Cargando…

Clinical evaluation of patients with moderate to severe Alzheimer disease

Today, Alzheimer disease has become a serious risk to individual and public health, due to the significant incapacity it causes patients, its influence on family members and caregivers, along with the ensuing direct and indirect costs. OBJECTIVES: To build the profile of patients with moderate/sever...

Descripción completa

Detalles Bibliográficos
Autores principales:	Varandas, Paulo Rogério Borges Rosmaninho, Funari, Rossana Russo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação de Neurologia Cognitiva e do Comportamento 2007
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619009/ https://www.ncbi.nlm.nih.gov/pubmed/29213404 http://dx.doi.org/10.1590/S1980-57642008DN10300012

Ejemplares similares

Evaluation of clinical comorbidities in cognitively impaired patients with depressive symptoms
por: Funari, Rossana Maria Russo, et al.
Publicado: (2007)

Reliability and validity of the severe impairment battery in Taiwanese patients with moderate to severe Alzheimer’s disease
por: Huang, Mao-Hsuan, et al.
Publicado: (2020)

Evaluating the treatment outcomes of repetitive transcranial magnetic stimulation in patients with moderate-to-severe Alzheimer’s disease
por: Zhang, Shouzi, et al.
Publicado: (2023)

Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer’s disease in the Netherlands
por: Hoogveldt, Bart, et al.
Publicado: (2011)

Correlation between asthma control and quality of life in patients with moderate and severe asthma
por: Valory, Mary Jane Lisboa, et al.
Publicado: (2015)

Analysis of word number and content in discourse of patients with mild to moderate Alzheimer's disease
por: de Lira, Juliana Onofre, et al.
Publicado: (2014)

Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity
por: Ferris, Steven, et al.
Publicado: (2013)

Synthesis and Comparison of the Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s Disease
por: Rive, Benoît, et al.
Publicado: (2013)

24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer’s Disease: Analyses from a Clinical Trial with Nabilone
por: Ruthirakuhan, Myuri, et al.
Publicado: (2019)

Rivastigmine in moderately severe-to-severe Alzheimer’s disease: Severe Impairment Battery factor analysis
por: Ferris, Steven, et al.
Publicado: (2013)

Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer's Disease: A Review of Clinical Trials
por: Molino, Ivana, et al.
Publicado: (2013)

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
por: Farlow, Martin, et al.
Publicado: (2011)

Effects of GV1001 on Language Dysfunction in Patients With Moderate-to-Severe Alzheimer’s Disease: Post Hoc Analysis of Severe Impairment Battery Subscales
por: Kwon, Hyuk Sung, et al.
Publicado: (2023)

Characteristics of falls in mild and moderate Alzheimer’s disease
por: Kato-Narita, Eliane Mayumi, et al.
Publicado: (2009)

Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region
por: Sabbagh, Marwan, et al.
Publicado: (2016)

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
por: Tariot, Pierre, et al.
Publicado: (2012)

Language impairment in the moderate stage of dementia due to Alzheimer's disease
por: ORTIZ, Karin Zazo, et al.
Publicado: (2021)

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease
por: Ballard, Clive, et al.
Publicado: (2019)

Naming ability in patients with mild to moderate Alzheimer's disease: what changes occur with the evolution of the disease?
por: Silagi, Marcela Lima, et al.
Publicado: (2015)

Combined application of tenuigenin and β-asarone improved the efficacy of memantine in treating moderate-to-severe Alzheimer’s disease
por: Chang, Wenguang, et al.
Publicado: (2018)

Neuropsychological Rehabilitation in Mild and Moderate Alzheimer’s Disease Patients
por: Ávila, Renata, et al.
Publicado: (2007)

Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer's Disease
por: Berk, Camryn, et al.
Publicado: (2012)

Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial)
por: Knapp, Martin, et al.
Publicado: (2016)

Clinical management and associated costs for moderate and severe Alzheimer’s disease in urban China: a Delphi panel study
por: Yu, Xin, et al.
Publicado: (2015)

Effect of Integrated Cognitive Intervention Therapy in Patients with Mild to Moderate Alzheimer's Disease
por: Jung, Young Hee, et al.
Publicado: (2020)

Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer’s Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors
por: Grossberg, George T., et al.
Publicado: (2018)

Real-world Evaluation of Tolerability, Safety and Efficacy of Rivastigmine Oral Solution in Patients with Mild to Moderate Alzheimer’s Disease Dementia
por: Hsieh, Sun-Wung, et al.
Publicado: (2021)

Identification of Potential Repurposable Drugs in Alzheimer’s Disease Exploiting a Bioinformatics Analysis
por: Fiscon, Giulia, et al.
Publicado: (2022)

Clinical characteristics of Japanese patients with moderate to severe COVID-19
por: Otoshi, Ryota, et al.
Publicado: (2021)

Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
por: Puangthong, Umamon, et al.
Publicado: (2009)

Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
por: Burstein, Aaron H, et al.
Publicado: (2014)

New Drugs from Marine Organisms in Alzheimer’s Disease
por: Russo, Patrizia, et al.
Publicado: (2015)

Evaluation of Activities of Daily Living/Instrumental Activities of Daily Living to Accurately Determine Severity of Moderate and Severe Alzheimer's Disease: Comparison of Assessments by Receiver Operating Characteristic Curve and Discriminant Analyses
por: Suzuki, Yukiko, et al.
Publicado: (2019)

Memantine treatment for Japanese patients with moderate to severe Alzheimer’s disease: a meta-analysis of double-blind, randomized, placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2018)

Cardiopulmonary exercise testing in patients with moderate-severe obesity: a clinical evaluation tool for OSA?
por: Vecchiato, Marco, et al.
Publicado: (2021)

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
por: Sabbagh, Marwan, et al.
Publicado: (2013)

Good rate of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease after three months of treatment: An open-label study
por: de Miranda, Luis Felipe José Ravic, et al.
Publicado: (2013)

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
por: Sabbagh, Marwan, et al.
Publicado: (2011)

Evaluation of Direct Oral Anticoagulant Prescribing in Patients With Moderate to Severe Renal Impairment
por: Ting, Clara, et al.
Publicado: (2021)

Cost-effectiveness analysis of the treatment of mild and moderate Alzheimer’s disease in Brazil
por: da Silva, Luciana R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_uj9htnau0qrvugelid8u6mbvmk